NCT04615455View on ClinicalTrials.gov

Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 3, 2020

Primary Completion Date

December 1, 2022

Study Completion Date

January 1, 2023

Conditions
Keratoconjunctivitis Sicca, in Sjogren's Syndrome
Interventions
DRUG

ASCs

ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml.

DRUG

Cryostor CS10

CryoStor® CS10 freeze medium

Trial Locations (1)

2200

Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER

NCT04615455 - Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome | Biotech Hunter | Biotech Hunter